Key TakeawaysThe new RSV immunization for infants is in high demand and short supply, which the manufacturer is working with the CDC to resolve.The immunization, called Beyfortus, is expensive and not all insurers are covering it yet.Pregnant people can get immunized during their third trimester to impart protection to their infants.

Key Takeaways

The new RSV immunization for infants is in high demand and short supply, which the manufacturer is working with the CDC to resolve.The immunization, called Beyfortus, is expensive and not all insurers are covering it yet.Pregnant people can get immunized during their third trimester to impart protection to their infants.

The scramble led the Centers for Disease Control (CDC) to issue a late October Health Alert Network (HAN) Health Advisory to reserve 100 milligram (mg) doses of the immunizations for the highest risk children: those under 6 months of age and those with underlying health conditions that make them more susceptible to RSV.

Here’s how it happened and what you can realistically do to get protected.

2 New Shots Will Protect Infants from RSV this Fall

Supply Issues

“It’s no longer available for us to order because it’s been spoken for,” Hackell told Verywell. “I’ve heard rumors that I can’t confirm that [Sanofi] isn’t planning on making any more this year.”

Sanofi has issueda statementclaiming they are working with the CDC and their manufacturer, AstraZeneca, to deliver additional doses, but as of October 26, they have not given a timeline of when more doses will be available.

Hackell said that most pediatricians have had much greater interest from parents in the RSV immunization than in shots such as the COVID vaccine.

What Does the RSV Shot Shortage Mean for People 60+?

A Matter of Cost

For physicians who still have doses of Beyfortus, there are additional roadblocks. Since Beyfortus is a monoclonal antibody and not technically a vaccine, some insurance companies are unsure how to classify it. Instead of covering it automatically and reimbursing physicians for the appropriate cost, some insurers are slowly deciding whether to cover the cost and how much to pay out.

This ambiguity is a sticking point for practitioners, as each dose of Beyfortus costs $495. Hackell said that many pediatricians are waiting to see if they will be reimbursed for the drug and, if so, how much.

“Some payers have indicated that they will be paying appropriately,” he said. “Others don’t have it loaded in the system, so you can’t find it. It’s not reasonable to expect pediatricians to commit to spending the money if they don’t know that if they administer it, they will get appropriately paid for it.”

Hackell said that while some insurance payers will say Beyfortus is covered, they may only commit to paying a portion of its cost, leaving pediatricians footing the bill for an expensive drug.

This federally-funded program provides vaccines at no cost to children who may not be able to pay for vaccines due to cost or lack of insurance. Physicians don’t have to pay for vaccines through VFC upfront. Hackell said that many pediatricians have supplies of Beyfortus for VFC children but don’t yet have it for privately insured patients.

“It becomes an equity issue,” Hackell said. “We can’t treat our patients the same way, and that doesn’t make us comfortable, but it’s the situation we’ve been placed in through no fault of our own because of the costs.”

A Secondary Solution

Until the supply of Beyfortus stabilizes, there is a secondary solution: vaccination while pregnant.Purvi Parikh, MD, medical director at Allergy and Asthma Associates of Murray Hill, says that pregnant people between32 and 36 weeks gestationare the ideal candidates for the adult RSV vaccine called Abrysvo. If given at least two weeks before birth, the parent will share antibodies across the placenta, providing enough protection that Beyfortus isn’t necessary.

Hackell said there have been few issues with the adult RSV vaccine, so the next hurdle is convincing parents to take it and let their children’s pediatricians know that they are vaccinated, eliminating the need for infant immunization.

What This Means For YouIf you’re currently pregnant, talk to your OB/GYN about Abrysvo. This is the most accessible way to transfer virus resistance to your child. If you’re searching for Beyfortus, talk to your pediatrician about whether your insurance is covering the drug and if it’s available, especially for children under 6 months old.

What This Means For You

If you’re currently pregnant, talk to your OB/GYN about Abrysvo. This is the most accessible way to transfer virus resistance to your child. If you’re searching for Beyfortus, talk to your pediatrician about whether your insurance is covering the drug and if it’s available, especially for children under 6 months old.

3 SourcesVerywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Suh M, Movva N, Jiang X, et al.Respiratory syncytial virus is the leading cause of United States infant hospitalizations, 2009-2019: a study of the National (Nationwide) Inpatient Sample.J Infect Dis. 2022;226(Suppl 2):S154-S163. doi:10.1093/infdis/jiac120Centers for Disease Control and Prevention.Limited availability of nirsevimab in the United States—interim CDC recommendations to protect infants from respiratory syncytial virus (RSV) during the 2023–2024 respiratory virus season.Centers for Disease Control and Prevention.CDC’s Vaccines for Children program addendum: special considerations for nirsevimab.

3 Sources

Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Suh M, Movva N, Jiang X, et al.Respiratory syncytial virus is the leading cause of United States infant hospitalizations, 2009-2019: a study of the National (Nationwide) Inpatient Sample.J Infect Dis. 2022;226(Suppl 2):S154-S163. doi:10.1093/infdis/jiac120Centers for Disease Control and Prevention.Limited availability of nirsevimab in the United States—interim CDC recommendations to protect infants from respiratory syncytial virus (RSV) during the 2023–2024 respiratory virus season.Centers for Disease Control and Prevention.CDC’s Vaccines for Children program addendum: special considerations for nirsevimab.

Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.

Suh M, Movva N, Jiang X, et al.Respiratory syncytial virus is the leading cause of United States infant hospitalizations, 2009-2019: a study of the National (Nationwide) Inpatient Sample.J Infect Dis. 2022;226(Suppl 2):S154-S163. doi:10.1093/infdis/jiac120Centers for Disease Control and Prevention.Limited availability of nirsevimab in the United States—interim CDC recommendations to protect infants from respiratory syncytial virus (RSV) during the 2023–2024 respiratory virus season.Centers for Disease Control and Prevention.CDC’s Vaccines for Children program addendum: special considerations for nirsevimab.

Suh M, Movva N, Jiang X, et al.Respiratory syncytial virus is the leading cause of United States infant hospitalizations, 2009-2019: a study of the National (Nationwide) Inpatient Sample.J Infect Dis. 2022;226(Suppl 2):S154-S163. doi:10.1093/infdis/jiac120

Centers for Disease Control and Prevention.Limited availability of nirsevimab in the United States—interim CDC recommendations to protect infants from respiratory syncytial virus (RSV) during the 2023–2024 respiratory virus season.

Centers for Disease Control and Prevention.CDC’s Vaccines for Children program addendum: special considerations for nirsevimab.

Meet Our Medical Expert Board

Share Feedback

Was this page helpful?Thanks for your feedback!What is your feedback?OtherHelpfulReport an ErrorSubmit

Was this page helpful?

Thanks for your feedback!

What is your feedback?OtherHelpfulReport an ErrorSubmit

What is your feedback?